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Background: Drug-eluting stents (DES) have been shown in randomized trials to significantly reduce the angiographic and clinical events in 
diabetic patients. However, there is insufficient data on similar outcomes in diabetics with small vessels.
Objectives: To analyze the effectiveness of DES in small vessels in patients with non-insulin-dependent diabetes mellitus (NIDDM) and insulin-
dependent diabetes mellitus (IDDM).
Methods: We studied 258 consecutive diabetic patients (173 NIDDM and 85 IDDM) who underwent coronary stenting with DES, divided into 2 
cohorts: Group A (vessels< 2.7 mm): 163 patients, and Group B (vessels ≥ 2.7 mm): 95 patients. We analyzed major coronary adverse events MACE 
(death, nonfatal myocardial infarction MI, and target vessel revascularization TVR) over a mean follow-up of 48.4 +/-14.8 months (maximum 84 
months).
Results: The patients’ characteristics were similar in both groups. Group A patients had: smaller reference diameter (2.4 ± 0.31 versus 3.14 ± 
0.2 mm, p=0.0001), longer lesions (19.3 ± 9.5 versus 16.7 ± 7.1 mm, p=0.023), more complex lesions: (B2/C) (80.7 versus 52.6%, p<0.033), 
bifurcation lesions (25.8 versus 11.6%, p=0.007), diffuse disease (42.9 versus 26.3%, p=0.008), multivessel (32.5 versus 18.9%, p=0.019), 
eccentric lesions (57.1 versus 43.2, p=0.031), more stents implanted (1.99 ± 1.6 versus 1.7 ± 1.3, p<0.0001), and more overlapping stents (29.4 
versus 13.7%, p=0.004). During the follow-up, both Groups had overall similar MACE (10.4 versus 11.6%, p=0.9) with insignificant higher restenosis 
(9.2 versus 8.4%, p=0.832) and TVR (7.4 versus 6.3%, p=0.75) in Group A. There was no differences in death (p=0.111) or MI (p=0.858). Both 
groups had similar stent thrombosis rate (1.2 versus 1.1%, p=0.899), angina events (10.4 versus 16.8%, p=0.137), abnormal stress Thallium (14.1 
versus 14.7%, p=0.890), and similar hospital days (2.91 versus 3.57, p=0.886).
Conclusions: Despite complex angiographic characteristics, the use of DES in diabetic patients with small vessel showed favorable clinical 
outcomes and similar low TVR compared to those with large vessel.
